Entos Pharmaceuticals receives funding for Phase I clinical trial of COVID-19 DNA Vaccine
Entos is seeking funding from government and investors to advance Covigenix through phase 2 and 3 human clinical trials
EDMONTON, Alta. — Entos Pharmaceuticals (Entos), a healthcare biotechnology company, announced on Oct. 23 that it is receiving advisory services and funding of up to $5M from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) as part of the Government of Canada’s continuing support for the development of domestic COVID-19 vaccine candidates.
Entos developed a Fusogenix DNA vaccine called Covigenix that in preclinical studies induces a strong neutralizing antibody response plus a potent and balanced T cell response against SARS-CoV-2, the virus that causes COVID-19. NRC IRAP’s support will help progress Entos’ COVID-19 DNA vaccine research to phase 1 human clinical trial to assess its safety at the Clinical Trials Research Center at the Canadian Center for Vaccinology (CCfV) in Nova Scotia.
“Entos is honoured to be one of the innovative Canadian companies receiving NRC IRAP support,” said John Lewis, CEO, Entos Pharmaceuticals, in a prepared statement. “We are excited to use this funding to advance the phase 1 human clinical trial of Covigenix at the Canadian Centre for Vaccinology.”
According to a statement, Entos is seeking funding from government and investors to advance Covigenix through phase 2 and 3 human clinical trials, accelerate upscaling of Covigenix GMP-manufacturing capacity, and promote distribution of millions of doses to the global population.